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Abstract: Universal HIV testing and immediate antiret-
roviral therapy for infected individuals has been proposed
as a way of reducing the transmission of HIV and thereby
bringing the HIV epidemic under control. It is unclear
whether transmission during early HIV infection—before
individuals are likely to have been diagnosed with HIV and
started on antiretroviral therapy—will compromise the
effectiveness of treatment as prevention. This article
presents two opposing viewpoints by Powers, Miller,
and Cohen, and Williams and Dye, followed by a
commentary by Fraser.
Introduction to the Debate
Triple-combination antiretroviral therapy (ART) first became
available in 1995 for the treatment of people living with HIV [1].
The fact that ART reduces viral load raised the prospect of using
ART not only to keep people alive, but also to control the
epidemic by annually testing everyone at risk of HIV infection and
immediately starting infected individuals on ART [2–4]. In 2011,
the HPTN 052 trial showed that ART reduced the risk of infection
in heterosexual HIV-serodiscordant couples (where one individual
is HIV-seropositive and the other is not) by 96% (95% confidence
interval [CI], 73% to 99%) and decisively confirmed the impact of
treatment on heterosexual transmission [5].
If the individual-level effects observed in the HPTN 052 trial are
to be successfully replicated at a population level, many operational
issues need to be addressed. An issue of particular importance
concerns transmission in the early stages of HIV infection, before an
individual is likely to be diagnosed with HIV and start receiving
treatment. Early HIV infection (EHI), the first 3–6 months after
infection, includes acute HIV infection (AHI), the period before the
development of antibodies to HIV, when the concentration of virus
in the plasma spikes and then falls to the set-point viral load.
Chronic HIV infection (CHI) comprises an asymptomatic period
following EHI, characterized by a stable viral load (,104.5 copies/
ml) and relatively low transmissibility, as well as late infection/
AIDS, when viral load and transmissibility are elevated again.
Different studies have arrived at widely differing estimates of the
proportion of HIV transmission events that occur during the first 3–
6 months after HIV infection, ranging from 5% to 95% [6]. High
levels of HIV transmission early in infection could compromise the
impact of universal testing and treatment on HIV transmission at a
population level, so it is essential to resolve this issue if ART is to be
used to help control the HIV pandemic.
In this debate, which specifically addresses heterosexual trans-
mission of HIV, Powers, Miller, and Cohen argue that up to 40% of
transmission takes place during EHI, and that this transmission will
compromise the effectiveness of treatment as prevention. Williams
and Dye argue that only about 2% of transmission takes place
during AHI, so that annual testing and immediate ART will be
sufficient to control the epidemic of HIV. In the final section,
Christophe Fraser summarizes and weighs in on the debate.
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Cohen’s Viewpoint: Acute and Early HIV Infection
Will Limit the Effectiveness of HIV Treatment as
Prevention
Although the use of ART to stop the spread of HIV has become
a major focus of HIV prevention, reliable empirical evidence to
support this strategy at the population level does not exist, and its
success in the real world may be limited by numerous factors [7].
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Here we focus on one particular factor: transmission during AHI
and EHI, which will not be affected by a treatment-as-prevention
approach. We argue that high levels of transmission during this
period of maximal infectiousness [6] will compromise the
effectiveness of HIV treatment as prevention.
Transmission Biology
HIV acquisition leads to a ramp-up in viremia to 10 million
copies/ml or more [8], with a subsequent cell-mediated immune
response that leads to decreased viral replication during asymptom-
atic infection [9]. The best available estimates of heterosexual HIV
transmission by infection stage, calculated among steady couples in
Rakai, Uganda, suggest that transmissibility is 26 times as high (95%
CI, 13–54) during EHI as it is in the subsequent asymptomatic
period [10]. Among the Rakai couples, the probability of a newly
infected person transmitting HIV to his or her partner in the first five
months of infection was estimated at 43% [11].
Importantly, the elevation in transmissibility observed during
EHI in Rakai is greater than would be expected based on viral
load alone [10]. If viral load were the only driver of infectiousness,
then we would expect transmission rates during AHI and EHI to
be only a few times higher than during chronic infection, as
Williams and Dye describe below. The mechanism for the
additional enhancement in transmissibility observed during EHI
in Rakai has not been elucidated, but there is evidence from
macaques that individual virions from EHI are 75–750 times as
infectious as virions from CHI [12].
Mathematical Modelling
Mathematical modelers have attempted to predict the potential
population benefits of ART [13]. With perhaps the most optimistic
model, Granich et al. have argued that universal annual HIV testing
and immediate ART would lead to HIV ‘‘elimination,’’ defined as
one incident infection per 1,000 persons annually, within ten years
in South Africa [4]. However, the analyses leading to this conclusion
failed to account for the effect of poor engagement in care [14] and
the increased infectiousness of persons with EHI [15], who would
not be reached by the test-and-treat strategy.
Modelling estimates of the percentage of new cases that are due
to contact with EHI index cases vary widely, depending on
epidemic stage, model structure, transmission mode, and EHI
definition. Most endemic-phase estimates have been in the range
of 5% to 40% [6], broadly consistent with estimates of 25%–50%
from phylogenetic studies [16]. However, the data available for
parameterizing most of these models have been limited. Using
behavioral and viral load data from Lilongwe, Malawi, as well as
the best available estimates of transmission efficiency by infection
stage [10], we constructed a mathematical model that allowed for
transmission both within and outside of steady heterosexual
relationships, substantial variation in transmissibility over the
course of infection, and heterogeneity in behavioral risk (rates of
partner change and contact within pairs) [15]. We used a Bayesian
melding procedure to account for input uncertainty, to fit the
model to empirical HIV prevalence data from Lilongwe, and to
express uncertainty around outputs.
In our model, we estimated that transmission rates were
elevated for 4.8 months (i.e., EHI lasted for 4.8 months) and that
38% (95% credible interval 19%–52%) of endemic-phase incident
infections arose from contact with EHI index cases annually. We
estimated that an annual test-and-treat strategy with very
optimistic chronic-phase coverage and engagement levels of 90%
or greater could substantially reduce HIV incidence, and
eventually prevalence, in this setting, but HIV elimination was
possible only at coverage and engagement levels of 99% or greater.
This prediction is consistent with the conclusion of Granich et al.
[4] and Williams and Dye (below) that with truly universal
coverage and engagement, annual test-and-treat strategies could
lead to HIV elimination. At more realistic coverage and
engagement levels (75%–85% of chronic-phase cases), however,
elimination did not occur in our model, but additional interven-
tions halting transmission during EHI led to marked, durable
reductions in HIV prevalence and incidence. Even in sensitivity
analyses where the contribution of EHI in Lilongwe was only half
our best estimate of 38% (19%), our results suggested that unless
test-and-treat coverage is essentially perfect, the impact of such
interventions is likely to be limited substantially by transmission
during EHI.
Williams et al. [17] recently argued (as Williams and Dye argue
below) that the 38% of cases we estimated to arise from contact with
EHI index cases is too high, proposing instead that only 2%–4% of
incident infections arise during AHI. By basing their calculations
only on the putative relationship between chronic-phase viral load
and transmissibility, they do not capture the greater-than-expected
transmissibility observed during EHI among the Rakai couples [10].
Furthermore, the duration (one month) and increase in transmission
rate per sexual encounter (three-fold) that they calculate for AHI
correspond to an expected within-couple transmission probability of
,3% during AHI (calculated as 12e2btd, where b=0.106 cases per
person-year, the asymptomatic-period transmission rate estimated
from the Rakai data [10]; t=3, the proposed relative increase in
transmissibility comparing AHI and asymptomatic infection [17]
and below; and d=1month, the proposed duration of AHI [17] and
below). This within-couple transmission probability of 3% during
AHI is dramatically lower than the 43% observed during EHI in
Rakai [11]. Simply put, the calculations of Williams and Dye are
inconsistent with the best available data from epidemiological,
mathematical, and phylogenetic studies regarding transmission
during EHI [6,10,11,16].
Implications for Treatment as Prevention
We believe that EHI can be expected to limit the impact of
treatment-as-prevention programs—at least in settings similar to
Lilongwe, Malawi—and that reductions in HIV incidence and
prevalence can be optimized through intervention packages that
stop transmission during both CHI and EHI. A number of
randomized trials to investigate the population-level effects of
treatment as prevention are underway [18]. Because they do not
include a specific strategy for dealing with AHI or EHI, the extent
to which they succeed will provide some indication as to whether
or not transmission during EHI compromises the effectiveness of
treatment as prevention. In addition, some of these studies will use
phylogenetic measurements to clarify transmission events attrib-
utable to acute/early cases versus chronic cases, providing more
specific information about the importance of AHI/EHI in the
context of these trials. If AHI and EHI are found to limit
treatment as prevention empirically, we will need to develop a
more efficient strategy for identifying individuals with EHI, as well
as credible behavioral and/or treatment-based intervention
strategies [19] for this period.
Brian G. Williams and Christopher Dye’s
Viewpoint: Acute and Early HIV Infection Will Not
Limit the Effectiveness of HIV Treatment as
Prevention
It has been shown that successful ART reduces heterosexual
transmission of HIV by 96% (95% CI, 73%–99%) [5], more than
enough to eliminate HIV transmission [4]. However, Powers et al.
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([15] and above) argue that 38% of transmission events occur during
the first 4.8 months after HIV acquisition and that unless HIV-
positive individuals start ART very early in this period, ART will
not be sufficient to eliminate HIV transmission. Here we argue that
(1) there is no convincing evidence to support their estimate of the
proportion of transmission events that take place during the first 4.8
months, and (2) even if their estimate is correct, annual testing and
immediate treatment would nevertheless be sufficient to eliminate
transmission
Transmission during Early HIV Infection
Twelve studies, summarized by Cohen et al. [6], suggest that
between 8% and 75% of new infections occur during EHI.
Unfortunately, all of the studies that are concerned with
heterosexual transmission depend on one set of data collected
from the retrospective identification of 23 couples in Rakai,
Uganda [11], in a study designed for other purposes. In ten
couples in the Rakai study, both partners seroconverted in the
same ten-month interval between testing. It was assumed that the
first person in the couple was infected after an average of five
months, leaving five months for them to infect their partner. Of
the 13 remaining serodiscordant couples, three of the seronegative
partners were infected in the next ten months, giving a rate ratio
for infection during the first and second periods of 7.3 (95% CI,
3.1–17.3) [11]. Allowance was made for the self-reported number
of sexual encounters, but not for the possibility that the second
person was infected from outside the relationship. Data from a
study of 23 couples, designed for other purposes, in which people
were tested for HIV only at ten-month intervals and were
identified retrospectively, which relied on self-reported sexual
activity, and which did not determine whether or not the infection
came from outside the relationship [11], do not provide a sound
basis for drawing conclusions about the importance of EHI.
Since there is no convincing direct evidence that heterosexual
transmission is higher during AHI than during the asymptomatic
period of CHI, we consider indirect estimates based on viral load
and the likely duration of AHI. Most new HIV infections are
established by a single founder virus. The concentration of virions in
the plasma then increases rapidly over three to four weeks, reaching
,106.5 copies/ml, and then falls equally rapidly to a set point at
,104.5 copies/ml [20,21]. From a preliminary analysis of data
presented by Robb [20] for people in the acute phase of infection,
the peak concentration of virus in the plasma is 102.1 (95%CI,101.6–
102.5) copies/ml times greater than at the set point, and AHI lasts
for 2.1 (1.6–2.5) weeks. Miller et al. [16] likewise observe that ‘‘acute
HIV infection, when the concentration of HIV in blood and genital
secretions is extremely high, is only a few weeks in duration.’’
According to the model of Powers et al. (Supplementary Web
Appendix Figure 1 in [15]), AHI , the period of peak viral load that
lasts for a maximum of six weeks, corresponding to an average
duration, with the same area under the curve, of two weeks, with
average viral load increased about 20-fold.
Transmission increases with viral load, and most authors assume
that transmission increases as viral load to the power of 0.3 to 0.5
[22–24]; the relationship is clearly sublinear so that transmission
saturates as viral load increases [25]. A more biologically plausible
model [26], which gives an equally good fit to the available data
[27], assumes that transmission increases linearly with viral load at
low values of viral load, but converges to an asymptote above a viral
load of 104.4 copies/ml [27]. In order to estimate Pi, the proportion
of infections that take place in stage i, we calculate, to first order,
Pi~
ridiP
i ridi
ð1Þ
where di is the duration and ri is the relative infectiousness of stage i,
assuming a steady state, in which prevalence, incidence, and
mortality are constant, and random mixing. With a mean set-point
viral load of 104.5 copies/ml, an increase in the average viremia
from 104.5 copies/ml to 106.5 copies/ml during AHI would make
little difference to the overall rate of transmission. Even if we
generously assume that the viral load peak during AHI lasts for one
month and that transmission rates per sexual encounter are
increased three-fold during AHI, Equation 1 shows that AHI
accounts for only 2% of all transmissions and would be
consequential only if people had several partners in the two-week
period of AHI, which is not supported by data. Raised viremia
during AHI does not support the claim that EHI contributes
significantly to heterosexual HIV transmission.
Powers et al. [15] estimate that EHI lasts for 4.8 months and
that during this time the risk of infection per sexual encounter is
30.3 (13.6–47.1) times greater than it is during the asymptomatic
period of CHI. If we grant these assumptions, Equation 1, which
assumes a steady state, shows that about 56% of infections would
then occur during EHI, in agreement with their estimate of 78%
(95% credible interval, 68%–85%) in 1975, falling to 38% (19%–
52%) in 2010. The agreement between this estimate using
Equation 1 and the estimate of Powers et al. [15] shows that our
Figure 1. The predicted effect of different levels of acute
infection on a combination prevention package including
universal testing and treatment, as will be tested in the
PopART trial [20]. (A) Green line: prevalence; red line: incidence.
Two versions of a model are fitted to the adult HIV prevalence curve for
South Africa (Joint United Nations Programme on HIV/AIDS): one
‘‘corrected’’ for serial monogamy effects in low-risk individuals [5], and
thus with a low contribution of AHI (solid line), and one without the
correction, and thus with a high contribution of AHI (dashed line). Fitted
parameters are as follows: the proportion of individuals in three risk
groups (low, medium, and high), rate of partner change for high-risk
individuals, assortativity of mixing by risk, start time, early treatment
rates, and an overall infectiousness parameter. Other parameters were
fixed from the literature [13,14]. (C) The intervention is introduced in
2012, and predictions are made until 2020, for three scenarios ranging
from the very pessimistic (green line), through ‘‘just on target’’ (red
line), to very optimistic (blue line). The results are surprisingly
independent of the amount of transmission from AHI, as indicated by
the solid versus dashed lines. (B and D) The contribution to transmission
from individuals in different disease stages in the just-on-target
scenarios is plotted in (B), corresponding to solid lines in (A) and (C)
(corrected for serial monogamy effects), and (D), corresponding to
dashed lines in (A) and (C) (not corrected for serial monogamy effects).
Shown are all new infections of index cases in AHI and EHI (green), of
index cases in untreated CHI (blue), and of index cases in treated CHI
(red), as a proportion of total new infections.
doi:10.1371/journal.pmed.1001232.g001
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different conclusions arise from our different estimates of the
duration of elevated infectiousness and transmission rates during
that period, and is not due to other structural details of the model.
Early Treatment and R0
Even if the modeled outcomes of Powers et al. [15] are correct,
annual testing and immediate treatment would still be sufficient to
eliminate transmission. The initial doubling time of the prevalence
of HIV in the Malawi study was 1.3 years ([15]), and the greater
the relative risk of transmission in EHI, the smaller must be the
value of the basic reproduction number, R0, to maintain the same
initial doubling time, as follows directly from the Euler-Lotka
equation [28,29]. If we suppose that transmission per sexual
contact is 30 times higher during EHI than during the next ten
years of CHI, as proposed by Powers et al. [15], the value of R0,
subject to the constraint that the initial doubling time is 1.3 years,
would have to be ,2 rather than ,5–10 [27]. Testing people at
regular intervals of one year and starting them immediately on
ART would reduce R0 to 0.8 [27]; testing people more frequently
would reduce it further. Thus, early treatment could still lead to
elimination of HIV transmission, and adding other interventions,
such as male circumcision, would increase the impact further.
Implications for Treatment as Prevention
There is agreement that ART reduces the rate of transmission
by about 25 times [5] and that this reduction is much greater than
has been demonstrated with any other currently available
intervention. It is unlikely that AHI or EHI significantly
compromises the impact of treatment on transmission. We agree
that if the intention is to start people on ART as soon as possible
after they become infected with HIV, ways of detecting people in
the acute phase of HIV infection would increase the impact of
treatment as prevention. Whatever may be the precise details of
transmission during AHI, treatment as prevention must now be
the cornerstone of HIV prevention programs. Going beyond
mathematical modelling, the magnitude of the effects of treatment
as prevention are being evaluated in a number of field trials [18].
We expect the results of these trials to offer, for the first time, the
prospect of an AIDS-free generation [30,31].
Christophe Fraser’s Commentary on the Debate
The role of AHI and EHI in transmission has been debated
since the early days of the HIV epidemic [32] and for much the
same reason is still debated today: it seems self-evidently important
but is hard to pin down. It is the subject of renewed attention in
light of growing interest in treatment as prevention, because unless
diagnosis can be made during AHI, most individuals will have
passed through EHI before universal testing and treatment would
start them on ART.
Powers et al. argue that EHI is a major driver of the epidemic,
while Williams and Dye suggest a minimal role for EHI; other
studies provide estimates across this range [6]. The debating
parties agree that data from the Rakai study in Uganda indicate
very high onward transmission in EHI, with 43% of couples found
to be mutually infected at the first follow-up after neither of them
was [11], and they agree that this is not consistent with
expectations from viral load alone [10]. Powers et al. support
the epidemiological observation (high transmission) and argue that
there is no reason to believe that viral load is a good marker for
infectiousness in EHI (true), while Williams and Dye support
arguments based on viral load and argue that, with only 23
couples, the Rakai study [11] is, in this context, too small to draw
such a strong conclusion (also true).
A pivotal point that neither party delves deeply enough into is the
effect of patterns of risk behavior. In a reanalysis of the Rakai data,
Hollingsworth et al. [10] show that low-risk (serial monogamy) and
high-risk (random mixing) contexts led to significantly different
estimates of the extent of transmission during EHI; Eaton et al. [33]
show that transmission in a sexual network with concurrent
partnerships produces intermediate estimates. Powers et al.
obtained higher estimates by allowing for complex correlations
between partner change rates and transmission probabilities per sex
act [15]. Finally, Koopman et al. [34] emphasize that assuming
constant sexual risk behavior over individuals’ lifetimes is neither
sensible nor supported by the data, and this too plays into the
estimation of the role of AHI, since if partner change rates decline
with age, EHI becomes more important.
While the role of different patterns of risk behavior in driving
EHI may have been underestimated, the argument made by
Williams and Dye that AHI and EHI do not matter to prevention
efforts as much as we might think may in fact be more
fundamental. This argument is based on the Euler-Lotka equation,
which constrains the relationship between growth rates and
generation times [35,36]. Here, I test this argument using a
conventional mathematical model of HIV transmission, which
extends earlier models [4,37] and is more complex than the
models that Williams and Dye have used in this context. Estimates
of transmission rates during EHI in the model are based on the
data from Rakai, which is still the best evidence to date on this
topic, and the model is fit to national surveillance data from South
Africa (from the Joint United Nations Programme on HIV/AIDS).
The model allows the rate of transmission during EHI to be
modified by turning on or off the correction factor for finite
Key Points
N Two opposing model-based viewpoints are presented
about whether transmission during early HIV infection is
likely to compromise the effectiveness of treatment as
prevention, i.e., using universal HIV testing and imme-
diate ART to halt the transmission of HIV in a population.
N Powers, Miller, and Cohen’s model suggests that 38% of
transmission takes place in the first few months after HIV
infection, i.e., before infections would be detected and
treated via annual testing and treatment, making early
HIV transmission a serious impediment to treatment as
prevention.
N Williams and Dye argue that their model shows that the
high levels of viremia during the acute phase of HIV
infection do not significantly increase HIV transmission
and that the risk of infection is not significantly higher
during early infection than it is during chronic infection.
They argue further that even if there were much higher
rates of transmission in the acute and early stages of
infection, early treatment would still be effective in
controlling the epidemic of HIV.
N Fraser highlights that the epidemiological contribution
of acute infection depends not just on infectiousness but
also on patterns of risk behavior. However, Fraser largely
concurs with Williams and Dye that the effect of acute
and early infection on the predicted impact of universal
testing and treatment may be much smaller than
expected.
N All authors agree that future modelling and empirical
studies will be useful in elucidating the impact of
treatment as prevention on the epidemic of HIV.
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partnerships amongst low- and medium-risk individuals [10]; this
is more efficient than increasing the parameter for the infectious-
ness of EHI, due to the counteracting effects of limited partnership
turnover on biological infectiousness. When the contribution of
EHI is tuned up or down, very different model projections result,
as expected.
However, changing our assumptions about the importance of
AHI and EHI not only affects our predictions about the future, but
also changes our interpretation of what has happened in the past:
each time the contribution of EHI is tuned up or down, the model
must be refitted to data. Figure 1 shows the outcome of this
process: it broadly confirms the prediction of the Euler-Lotka
equation in the context of a more complex mathematical model,
validating the hypothesis of Williams and Dye that the total
effectiveness of treatment as prevention depends surprisingly little
on the effect of EHI on transmission.
It must be stated that these predictions are based on a model
that is still relatively simple, and reality may yet surprise us.
Further modelling work could play a useful role by determining
more systematically under which circumstances the prediction of
the Euler-Lotka equation is or is not expected to hold, and guiding
the collection of appropriate data. Treatment as prevention holds
extraordinary promise, but will also be expensive and challenging
to deliver in many settings. Arguments about potential barriers to
success, such as presented in this debate, need careful consider-
ation. Population-based trials, such as PopART (HPTN 071) [38]
and others [18] that are being planned, as well as more
observational data, will provide much needed empirical tests of
the proposal that treatment as prevention is feasible and effective.
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